CD274 and neoplasm: The exploration of gene expression profiles, the tumor mutational burden, PD-L1 and other biomarkers have yielded great progress in predicting patient prognosis and immunotherapy efficacy, but there are still some problems that make it difficult to meet clinical needs (18, 19).